In vivo tissue-tropism of adeno-associated viral vectors

Current Opinion in Virology

Volumn 21, Issue , 2016, Pages 75-80

  Srivastava, Arun ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; PARVOVIRUS VECTOR; VIRUS RECEPTOR;

ADENO ASSOCIATED VIRUS 2; HUMAN; IN VIVO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRAL GENE THERAPY; VIRAL TROPISM; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; METABOLISM; PHYSIOLOGY; VIRUS ATTACHMENT; VIRUS ENTRY;

DEPENDOVIRUS; GENETIC VECTORS; HUMANS; RECEPTORS, VIRUS; VIRAL TROPISM; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 84985993659     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.08.003     Document Type: Review

References (86)

1. 1 Atchison, R.W., Casto, B.C., Hammon, W.M., Adenovirus-associated defective virus particles. Science 149 (1965), 754–756.
2. 2•• Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., Petersen-Jones, S., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239 This paper, and the next four papers, describe the first successful use of recombinant AAV2 vectors to achieve clinical efficacy in Phase I trials in patients with Leber's congenital amaurosis.
3. 3 Cideciyan, A.V., Aleman, T.S., Boye, S.L., Schwartz, S.B., Kaushal, S., Roman, A.J., Pang, J.J., Sumaroka, A., Windsor, E.A., Wilson, J.M., Flotte, T.R., et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 105 (2008), 15112–15117.
4. 4 Hauswirth, W.W., Aleman, T.S., Kaushal, S., Cideciyan, A.V., Schwartz, S.B., Wang, L., Conlon, T.J., Boye, S.L., Flotte, T.R., Byrne, B.J., Jacobson, S.G., Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase i trial. Hum Gene Ther 19 (2008), 979–990.
5. 5 Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M., Rossi, S., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
6. 6•• Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., O'Beirne, J., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365 This paper describes the first successful use of recombinant AAV8 vectors to achieve clinical efficacy in a Phase I trial in patients with hemophilia B.
7. 7 Hwu, W.L., Muramatsu, S., Tseng, S.H., Tzen, K.Y., Lee, N.C., Chien, Y.H., Snyder, R.O., Byrne, B.J., Tai, C.H., Wu, R.M., Gene therapy for aromatic l-amino acid decarboxylase deficiency. Sci Transl Med, 4, 2012, 134ra161.
8. 8 Gaudet, D., Methot, J., Dery, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., Sier-Ferreira, V., et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447x) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20 (2013), 361–369.
9. 9 MacLaren, R.E., Groppe, M., Barnard, A.R., Cottriall, C.L., Tolmachova, T., Seymour, L., Clark, K.R., During, M.J., Cremers, F.P., Black, G.C., Lotery, A.J., et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383 (2014), 1129–1137.
10. 10• Feuer, W.J., Schiffman, J.C., Davis, J.L., Porciatti, V., Gonzalez, P., Koilkonda, R.D., Yuan, H., Lalwani, A., Lam, B.L., Guy, J., Gene therapy for leber hereditary optic neuropathy: initial results. Ophthalmology 123 (2016), 558–570 This paper describes the results of the first human clinical trial with capsid-modified AAV2 vectors.
11. 11• Ponnazhagan, S., Wang, X.S., Woody, M.J., Luo, F., Kang, L.Y., Nallari, M.L., Munshi, N.C., Zhou, S.Z., Srivastava, A., Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. J Gen Virol 77:Pt 6 (1996), 1111–1122 This paper describes the first human cell line that could not be infected by AAV2, or transduced by recombinant AAV2 vectors, suggesting for the first time that AAV2 infection of human cells was receptor-mediated.
12. 12 Mizukami, H., Young, N.S., Brown, K.E., Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology 217 (1996), 124–130.
13. 13• Summerford, C., Samulski, R.J., Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72 (1998), 1438–1445 This paper describes the identification of the first cellular receptor for AAV2.
14. 14• Flotte, T., Carter, B., Conrad, C., Guggino, W., Reynolds, T., Rosenstein, B., Taylor, G., Walden, S., Wetzel, R., A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 7 (1996), 1145–1159 This paper describes the first use of recombinant AAV2 vectors in a Phase I clinical trial in patients with cystic fibrosis. This trial established the safety of recombinant AAV2 vectors in humans.
15. 15 Duan, D., Yue, Y., Yan, Z., McCray, P.B. Jr., Engelhardt, J.F., Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther 9 (1998), 2761–2776.
16. 16• Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., Srivastava, A., Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5 (1999), 71–77 This paper describes the identification of the first cellular co-receptor for AAV2.
17. 17 Summerford, C., Bartlett, J.S., Samulski, R.J., AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5 (1999), 78–82.
18. 18 Chen, C.L., Jensen, R.L., Schnepp, B.C., Connell, M.J., Shell, R., Sferra, T.J., Bartlett, J.S., Clark, K.R., Johnson, P.R., Molecular characterization of adeno-associated viruses infecting children. J Virol 79 (2005), 14781–14792.
19. 19 Muzyczka, N., Warrington, K.H. Jr., Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 16 (2005), 408–416.
20. 20 Boye, S.L., Bennett, A., Scalabrino, M.L., McCullough, K.T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., Boye, S.E., The impact of heparan sulfate binding on transduction of retina by rAAV vectors. J Virol, 2016.
21. 21 Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., Daida, H., Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79 (2005), 609–614.
22. 22 Asokan, A., Hamra, J.B., Govindasamy, L., Agbandje-McKenna, M., Samulski, R.J., Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 80 (2006), 8961–8969.
23. 23 Akache, B., Grimm, D., Pandey, K., Yant, S.R., Xu, H., Kay, M.A., The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80 (2006), 9831–9836.
24. 24 Kurzeder, C., Koppold, B., Sauer, G., Pabst, S., Kreienberg, R., Deissler, H., CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Int J Mol Med 19 (2007), 325–333.
25. 25 Xiao, W., Chirmule, N., Berta, S.C., McCullough, B., Gao, G., Wilson, J.M., Gene therapy vectors based on adeno-associated virus type 1. J Virol 73 (1999), 3994–4003.
26. 26 Muramatsu, S., Mizukami, H., Young, N.S., Brown, K.E., Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 221 (1996), 208–217.
27. 27 Chiorini, J.A., Yang, L., Liu, Y., Safer, B., Kotin, R.M., Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant aav4 particles. J Virol 71 (1997), 6823–6833.
28. 28 Bantel-Schaal, U., Delius, H., Schmidt, R., zur Hausen, H., Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J Virol 73 (1999), 939–947.
29. 29 Rutledge, E.A., Halbert, C.L., Russell, D.W., Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than aav type 2. J Virol 72 (1998), 309–319.
30. 30•• Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J., Wilson, J.M., Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99 (2002), 11854–11859 This paper describes the discovery of novel AAV serotype vectors.
31. 31 Mori, S., Wang, L., Takeuchi, T., Kanda, T., Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330 (2004), 375–383.
32. 32 Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., Chiorini, J.A., Adeno-associated virus type 12 (AAV12): a novel aav serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 82 (2008), 1399–1406.
33. 33 Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., Chiorini, J.A., Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J Virol 82 (2008), 8911–8916.
34. 34 Chen, S., Kapturczak, M., Loiler, S.A., Zolotukhin, S., Glushakova, O.Y., Madsen, K.M., Samulski, R.J., Hauswirth, W.W., Campbell-Thompson, M., Berns, K.I., Flotte, T.R., et al. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 16 (2005), 235–247.
35. 35 Wu, Z., Miller, E., Agbandje-McKenna, M., Samulski, R.J., Alpha2,3 and alpha2,6 n-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80 (2006), 9093–9103.
36. 36 Handa, A., Muramatsu, S., Qiu, J., Mizukami, H., Brown, K.E., Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with aav-2-based vectors. J Gen Virol 81:Pt 8 (2000), 2077–2084.
37. 37 Kaludov, N., Handelman, B., Chiorini, J.A., Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 13 (2002), 1235–1243.
38. 38 Walters, R.W., Yi, S.M., Keshavjee, S., Brown, K.E., Welsh, M.J., Chiorini, J.A., Zabner, J., Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276 (2001), 20610–20616.
39. 39 Walters, R.W., Pilewski, J.M., Chiorini, J.A., Zabner, J., Secreted and transmembrane mucins inhibit gene transfer with aav4 more efficiently than AAV5. J Biol Chem 277 (2002), 23709–23713.
40. 40 Seiler, M.P., Miller, A.D., Zabner, J., Halbert, C.L., Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum Gene Ther 17 (2006), 10–19.
41. 41 Wu, Z., Asokan, A., Samulski, R.J., Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14 (2006), 316–327.
42. 42 Shen, S., Bryant, K.D., Brown, S.M., Randell, S.H., Asokan, A., Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286 (2011), 13532–13540.
43. 43 Bell, C.L., Gurda, B.L., Van Vliet, K., Agbandje-McKenna, M., Wilson, J.M., Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol 86 (2012), 7326–7333.
44. 44 Shen, S., Berry, G.E., Castellanos Rivera, R.M., Cheung, R.Y., Troupes, A.N., Brown, S.M., Kafri, T., Asokan, A., Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. J Biol Chem 290 (2015), 1496–1504.
45. 45 Blackburn, S.D., Steadman, R.A., Johnson, F.B., Attachment of adeno-associated virus type 3B to fibroblast growth factor receptor 1. Arch Virol 151 (2006), 617–623.
46. 46 Ling, C., Lu, Y., Kalsi, J.K., Jayandharan, G.R., Li, B., Ma, W., Cheng, B., Gee, S.W., McGoogan, K.E., Govindasamy, L., Zhong, L., et al. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther 21 (2010), 1741–1747.
47. 47 Di Pasquale, G., Davidson, B.L., Stein, C.S., Martins, I., Scudiero, D., Monks, A., Chiorini, J.A., Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9 (2003), 1306–1312.
48. 48 Weller, M.L., Amornphimoltham, P., Schmidt, M., Wilson, P.A., Gutkind, J.S., Chiorini, J.A., Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 16 (2010), 662–664.
49. 49 Nonnenmacher, M., Weber, T., Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10 (2011), 563–576.
50. 50• Pillay, S., Meyer, N.L., Puschnik, A.S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L.T., Wosen, J.E., Nagamine, C.M., Chapman, M.S., Carette, J.E., An essential receptor for adeno-associated virus infection. Nature 530 (2016), 108–112 This paper describes the identification of a cell membrane receptor involved in the entry of multiple AAV serotypes.
51. 51 Zincarelli, C., Soltys, S., Rengo, G., Rabinowitz, J.E., Analysis of aav serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16 (2008), 1073–1080.
52. 52 Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O'Malley, K.L., During, M.J., Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8 (1994), 148–154.
53. 53 Ali, R.R., Reichel, M.B., Thrasher, A.J., Levinsky, R.J., Kinnon, C., Kanuga, N., Hunt, D.M., Bhattacharya, S.S., Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 5 (1996), 591–594.
54. 54 Kessler, P.D., Podsakoff, G.M., Chen, X., McQuiston, S.A., Colosi, P.C., Matelis, L.A., Kurtzman, G.J., Byrne, B.J., Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 93 (1996), 14082–14087.
55. 55 Lalwani, A.K., Walsh, B.J., Reilly, P.G., Muzyczka, N., Mhatre, A.N., Development of in vivo gene therapy for hearing disorders: introduction of adeno-associated virus into the cochlea of the guinea pig. Gene Ther 3 (1996), 588–592.
56. 56 Conrad, C.K., Allen, S.S., Afione, S.A., Reynolds, T.C., Beck, S.E., Fee-Maki, M., Barrazza-Ortiz, X., Adams, R., Askin, F.B., Carter, B.J., Guggino, W.B., et al. Safety of single-dose administration of an adeno-associated virus (aav)-cftr vector in the primate lung. Gene Ther 3 (1996), 658–668.
57. 57 Koeberl, D.D., Alexander, I.E., Halbert, C.L., Russell, D.W., Miller, A.D., Persistent expression of human clotting factor ix from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 94 (1997), 1426–1431.
58. 58• Ponnazhagan, S., Mukherjee, P., Yoder, M.C., Wang, X.S., Zhou, S.Z., Kaplan, J., Wadsworth, S., Srivastava, A., Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 190 (1997), 203–210 This paper describes the hepatotropic nature of recombinant AAV2 vectors.
59. 59 Snyder, R.O., Miao, C.H., Patijn, G.A., Spratt, S.K., Danos, O., Nagy, D., Gown, A.M., Winther, B., Meuse, L., Cohen, L.K., Thompson, A.R., et al. Persistent and therapeutic concentrations of human factor ix in mice after hepatic gene transfer of recombinant aav vectors. Nat Genet 16 (1997), 270–276.
60. 60 Ponnazhagan, S., Yoder, M.C., Srivastava, A., Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo. J Virol 71 (1997), 3098–3104.
61. 61 Rubenstein, R.C., McVeigh, U., Flotte, T.R., Guggino, W.B., Zeitlin, P.L., Cftr gene transduction in neonatal rabbits using an adeno-associated virus (aav) vector. Gene Ther 4 (1997), 384–392.
62. 62 Halbert, C.L., Standaert, T.A., Aitken, M.L., Alexander, I.E., Russell, D.W., Miller, A.D., Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 71 (1997), 5932–5941.
63. 63 Rolling, F., Nong, Z., Pisvin, S., Collen, D., Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther 4 (1997), 757–761.
64. 64 Polyak, S., Mah, C., Porvasnik, S., Herlihy, J.D., Campbell-Thompson, M., Byrne, B.J., Valentine, J.F., Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig Dis Sci 53 (2008), 1261–1270.
65. 65 Prasad, K.M., Yang, Z., Bleich, D., Nadler, J.L., Adeno-associated virus vector mediated gene transfer to pancreatic beta cells. Gene Ther 7 (2000), 1553–1561.
66. 66 Voutetakis, A., Kok, M.R., Zheng, C., Bossis, I., Wang, J., Cotrim, A.P., Marracino, N., Goldsmith, C.M., Chiorini, J.A., Loh, Y.P., Nieman, L.K., et al. Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. Proc Natl Acad Sci U S A 101 (2004), 3053–3058.
67. 67 Wagner, J.A., Messner, A.H., Moran, M.L., Daifuku, R., Kouyama, K., Desch, J.K., Manley, S., Norbash, A.M., Conrad, C.K., Friborg, S., Reynolds, T., et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109:Pt 1 (1999), 266–274.
68. 68 Dai, J., Rabie, A.B., Direct AAV-mediated gene delivery to the temporomandibular joint. Front Biosci 12 (2007), 2212–2220.
69. 69 Li, J., Dressman, D., Tsao, Y.P., Sakamoto, A., Hoffman, E.P., Xiao, X., rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 6 (1999), 74–82.
70. 70 Lin, C.Y., Ho, C.H., Hsieh, Y.H., Kikuchi, T., Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency. Gene Ther 9 (2002), 554–563.
71. 71 Shimazaki, K., Urabe, M., Monahan, J., Ozawa, K., Kawai, N., Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: prospects for gene therapy of ischemia-induced neuronal death. Gene Ther 7 (2000), 1244–1249.
72. 72 Vite, C.H., Passini, M.A., Haskins, M.E., Wolfe, J.H., Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 10 (2003), 1874–1881.
73. 73 Monahan, P.E., Samulski, R.J., Tazelaar, J., Xiao, X., Nichols, T.C., Bellinger, D.A., Read, M.S., Walsh, C.E., Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 5 (1998), 40–49.
74. 74 Mori, S., Takeuchi, T., Enomoto, Y., Kondo, K., Sato, K., Ono, F., Iwata, N., Sata, T., Kanda, T., Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys. Jpn J Infect Dis 59 (2006), 285–293.
75. 75• Manno, C.S., Chew, A.J., Hutchison, S., Larson, P.J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M., Couto, L.B., et al. AAV-mediated factor ix gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003), 2963–2972 This paper describes the first use of recombinant AAV2 vectors in a Phase I trial for musle-directed gene delivery.
76. 76• Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 12 (2006), 342–347 This paper describes the first use of recombinant AAV2 vectors in a Phase I trial for liver-directed gene delivery.
77. 77 Kaiser, J., Clinical trials. Gene transfer an unlikely contributor to patient's death. Science, 318, 2007, 1535.
78. 78•• Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., et al. Long-term safety and efficacy of factor ix gene therapy in hemophilia B. N Engl J Med 371 (2014), 1994–2004 This paper describes the long-term safety and efficacy of recombinant AAV8 vectors in patients with hemophilia B.
79. 79 Flotte, T.R., Trapnell, B.C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A.T., Sandhaus, R.A., McElvaney, N.G., Mueller, C., et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 22 (2011), 1239–1247.
80. 80 Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., Lawson, L.A., Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAV1-CMV-GAA) gene vector in patients with pompe disease. Hum Gene Ther Clin Dev 25 (2014), 134–163.
81. 81 Corti, M., Cleaver, B., Clement, N., Conlon, T.J., Faris, K.J., Wang, G., Benson, J., Tarantal, A.F., Fuller, D., Herzog, R.W., Byrne, B.J., Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev 26 (2015), 185–193.
82. 82• Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., Flotte, T.R., et al. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol Ther 23 (2015), 1867–1876 This and the next paper describe that recombinant AAV3 vectors selectively and efficiently transduce the liver in non-human primates following intravenous delivery.
83. 83 Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., Wilson, J.M., Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther 23 (2015), 1877–1887.
84. 84•• Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner-Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., de Jong, Y.P., et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther 24 (2016), 1042–1049 This paper describes the first direct comparison of the efficiencies of recombinant AAV3, AAV5, AAV8, and AAV9 vectors in primary human hepatocytes in a humanized mouse model.
85. 85 Ginn, S.L., Alexander, I.E., Edelstein, M.L., Abedi, M.R., Wixon, J., Gene therapy clinical trials worldwide to 2012 — an update. J Gene Med 15 (2013), 65–77.
86. 86•• Srivastava, A., Adeno-associated virus: the naturally occurring virus versus the recombinant vector. Hum Gene Ther 27 (2016), 1–6 This paper describes strategies to develop novel AAV serotype vectors capable of higher transduction efficiency at lower doses; lower immunogenicity; and lower production cost per patient.